David Bruce Kudrow MD
Headache
Director, California Medical Clinic for Headache. Director, Headache Clinic Harbor-UCLA Medical Center. Assistant Clinical Professor in Neurology UCLA David Geffen School of Medicine.
Join to view full profile
2080 Century Park EastSuite 805Los Angeles, CA 90067
Phone+1 310-315-1456
Fax+1 310-315-1486
Dr. Kudrow is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Kudrow is a neurologist in Century City, CA and is affiliated with Providence Saint John's Health Center. He received his medical degree from University of Southern California School of Medicine and has been in practice 35 years. He specializes in headache and is experienced in migraine disorders and headache disorders.
Education & Training
Los Angeles County-Harbor-UCLA Medical CenterResidency, Neurology, 1987 - 1991
UCLA-VA Greater Los AngelesInternship, Internal Medicine, 1986 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1986
Certifications & Licensure
IL State Medical License 2019 - 2029
MT State Medical License 2020 - 2028
NY State Medical License 2018 - 2028
TX State Medical License 2020 - 2028
UT State Medical License 2019 - 2028
AZ State Medical License 2021 - 2027
CA State Medical License 1988 - 2027
American Board of Psychiatry and Neurology Neurology- Join now to see all
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
Publications & Presentations
PubMed
- Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.Amaal J Starling, David Kudrow, Neha Kapur, Susanne F Awad, S Wald Grossman
Pain and Therapy. 2026-06-01 - 12 citationsA 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.David Kudrow, Robert S Croop, Alexandra Thiry, Richard B Lipton
Headache. 2026-02-01 - Oral rimegepant as a preventive treatment of migraine: a plain language summary of a clinical study.Robert Croop, Richard B Lipton, David Kudrow, Lisa Kamen, Charles M Conway
Pain Management. 2025-09-01
Press Mentions
Long-Term Rimegepant Use Safe for Migraine PreventionJuly 17th, 2025- Long-Term Safety and Tolerability of Eptinezumab in Patients with Chronic Migraine: A 2-Year, Open-Label, Phase 3 TrialMarch 19th, 2021
FDA Approves Galcanezumab-Gnlm for Episodic Cluster HeadacheJune 5th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
